Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Pharmacogenetics of childhood acute lymphoblastic leukemia.

Lopez-Lopez E, Gutierrez-Camino A, Bilbao-Aldaiturriaga N, Pombar-Gomez M, Martin-Guerrero I, Garcia-Orad A.

Pharmacogenomics. 2014 Jul;15(10):1383-98. doi: 10.2217/pgs.14.106. Review.

PMID:
25155938
2.

Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.

He HR, Liu P, He GH, Dong WH, Wang MY, Dong YL, Lu J.

Leuk Lymphoma. 2014 Dec;55(12):2793-800. doi: 10.3109/10428194.2014.898761. Epub 2014 Apr 3.

PMID:
24597986
3.

Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?

Kodidela S, Suresh Chandra P, Dubashi B.

Eur J Clin Pharmacol. 2014 Mar;70(3):253-60. doi: 10.1007/s00228-013-1623-4. Epub 2013 Dec 27. Review.

PMID:
24370659
4.

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.

Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Möricke A, Stanulla M, Schrappe M, Langer T.

Blood. 2013 Jun 27;121(26):5145-53. doi: 10.1182/blood-2013-01-480335. Epub 2013 May 7.

5.

Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.

Aplenc R, Lange B.

Br J Haematol. 2004 May;125(4):421-34. Review.

PMID:
15142113
6.

Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.

Salazar J, Altés A, del Río E, Estella J, Rives S, Tasso M, Navajas A, Molina J, Villa M, Vivanco JL, Torrent M, Baiget M, Badell I.

Pharmacogenomics J. 2012 Oct;12(5):379-85. doi: 10.1038/tpj.2011.25. Epub 2011 Jul 12.

PMID:
21747412
7.

The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.

Niedzielska E, Węcławek-Tompol J, Matkowska-Kocjan A, Chybicka A.

Adv Clin Exp Med. 2013 Jul-Aug;22(4):579-84. Review.

8.

Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.

Csordas K, Lautner-Csorba O, Semsei AF, Harnos A, Hegyi M, Erdelyi DJ, Eipel OT, Szalai C, Kovacs GT.

Br J Haematol. 2014 Aug;166(3):410-20. doi: 10.1111/bjh.12886. Epub 2014 Apr 9.

PMID:
24712521
9.

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.

Davidsen ML, Dalhoff K, Schmiegelow K.

J Pediatr Hematol Oncol. 2008 Nov;30(11):831-49. doi: 10.1097/MPH.0b013e3181868570. Review.

PMID:
18989161
10.

Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.

Erčulj N, Kotnik BF, Debeljak M, Jazbec J, Dolžan V.

Leuk Lymphoma. 2012 Jun;53(6):1096-104. doi: 10.3109/10428194.2011.639880. Epub 2012 Feb 3.

PMID:
22074251
11.
12.

Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.

Yang JJ, Bhojwani D.

Methods Mol Biol. 2013;999:273-84. doi: 10.1007/978-1-62703-357-2_20.

PMID:
23666706
13.

Ancestry and pharmacogenetics of antileukemic drug toxicity.

Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV.

Blood. 2007 May 15;109(10):4151-7. Epub 2007 Jan 30.

14.

Pharmacogenomics of pediatric acute lymphoblastic leukemia.

Meeker ND, Yang JJ, Schiffman JD.

Expert Opin Pharmacother. 2010 Jul;11(10):1621-32. doi: 10.1517/14656566.2010.484019. Review.

PMID:
20429672
15.

Pharmacogenetics of acute lymphoblastic leukemia.

Mehta PA, Davies SM.

Curr Opin Hematol. 2004 Nov;11(6):434-8. Review.

PMID:
15548999
16.

Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.

D'Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M, Affinita MC, Pecoraro G, Napolitano A, Fusco C, Oreste M, Indolfi C, Casale F.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1339-46. doi: 10.1007/s00280-011-1665-1. Epub 2011 May 18.

PMID:
21590445
17.

Pharmacogenetics in acute lymphoblastic leukemia.

Cheok MH, Pottier N, Kager L, Evans WE.

Semin Hematol. 2009 Jan;46(1):39-51. doi: 10.1053/j.seminhematol.2008.09.002. Review.

18.

Pharmacogenetics of acute lymphoblastic leukemia treatment response.

Cunningham L, Aplenc R.

Expert Opin Pharmacother. 2007 Oct;8(15):2519-31. Review.

PMID:
17931087
19.

Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.

Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Abboud MR, Solh H, Muwakkit SA.

Pharmacogenet Genomics. 2014 Aug;24(8):387-96. doi: 10.1097/FPC.0000000000000069.

PMID:
25007187
20.

Pharmacogenomics of acute leukemia.

Ansari M, Krajinovic M.

Pharmacogenomics. 2007 Jul;8(7):817-34. doi: 10.2217/14622416.8.7.817. Review.

PMID:
18240908
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk